Tests:Alpha Fetoprotein, Tumor Marker: Difference between revisions

Tests:Alpha Fetoprotein, Tumor Marker
No edit summary
No edit summary
 
(9 intermediate revisions by 4 users not shown)
Line 5: Line 5:
{| class="wikitable"
{| class="wikitable"
! colspan="2" |
! colspan="2" |
===Overview===
== Overview ==
|-
|-
|Department
|Department
|Biochemistry 
|Biochemistry                                                                                                                         
|-
|-
|Test Code
|Test Code
Line 16: Line 16:
|Tumour Marker (AFP)
|Tumour Marker (AFP)
AFP (tumour marker)
AFP (tumour marker)
|-
|Availability
|Performed Mon-Fri. Available out of hours except weekends and public holidays
|-
|-
|Turnaround Time
|Turnaround Time
Line 21: Line 24:
|-
|-
|Stability – Add test
|Stability – Add test
|
|24 hours
|-
|-
! colspan="2" |''Specimen Requirements''
! colspan="2" |
== Specimen Requirements ==
|-
|-
|Specimen Type
|Specimen  
|Serum
|Serum
Plasma
|-
|-
|Preferred
|Preferred
|7 mL Plain <span style="background:#e30022"> red-top </span>
|Plain Yellow-top or <span style="background:#e30022"> Red-Top </span> tube
|-
|-
|Acceptable
|Acceptable
|
|Plain Yellow-top or <span style="background:#e30022"> Red-Top </span> tube
|-
|Unacceptable
|Plasma samples
|-
|-
|Pediatric Requirements
|Paediatric Requirements
|0.5 mL <span style="background:#99e6b3"> Li Hep Microtainer </span>
|0.5 mL paediatric <span style="background:#e30022">Red-Top </span>
|-
|-
! colspan="2" |''Aliquot Requirements''
! colspan="2" |
== Aliquot Requirements ==
|-
|-
|Sample Type
|Sample
|Serum 
|Serum 
|-
|Preferred Volume
|>500 µL
|-
|-
|Minimum Volume
|Minimum Volume
Line 49: Line 59:
|
|
|-
|-
! colspan="2" |''Clinical Information''
! colspan="2" |== Clinical Information ==
|-
|-
|Reference Intervals
|Reference Intervals
Line 57: Line 67:
|-
|-
|Test Method
|Test Method
|Ci8200 analyser, Abbott Reagent.   
|Abbott Alinity i series analyser using Abbott reagents.  Chemiluminescent microparticle immunoassay.
|-
|-
|Advanced Notice
|Advanced Notice
Line 65: Line 75:
|Not required
|Not required
|-
|-
! colspan="2" |''Comments''
! colspan="2" |
== Comments ==
|-
|-
| colspan="2" | This test is useful as a tumour marker and as a safe and effective supplement to the management of patients undergoing treatment for non-seminomatous testicular cancer and  
| colspan="2" | This test is useful as a tumour marker and as a safe and effective supplement to the management of patients undergoing treatment for non-seminomatous testicular cancer and
certain germ cell cancers, or for patients being monitored after therapy is complete. 


certain germ cell cancers, or for patients being monitored after therapy is complete. The test is NOT a screening test for cancer.   
The test is NOT a screening test for cancer.   


The test is NOT intended as a screen for neural tube defects.  
The test is NOT intended as a screen for neural tube defects.  
Line 75: Line 87:
For the serial monitoring of tumours, tumour markers should be tested in the same laboratory.
For the serial monitoring of tumours, tumour markers should be tested in the same laboratory.
|}
|}
{{DocMeta
| owner = Crossley1
| review_ping =
}}